title: Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy.
abstract: To compare three quantitative assays measuring viral load in patients with chronic hepatitis C and to determine their value in predicting response to interferon (IFN) therapy, we analysed serum from 896 patients from eight European Centres using QUANTIPLEXtrade mark bDNA, MONITOR AMPLICORtrade mark and SUPERQUANTtrade mark assays. Analyses were performed on the same sample. Viral genotype was assessed using INNO-LiPA HCV II kits. Intercentre variations were observed that were related to the handling of specimens not processed and stored within 6 h of blood sampling. Among sera with optimal handling, a stronger correlation was observed between bDNA and SUPERQUANT (0.806) than between bDNA and MONITOR (0.677) and between MONITOR and SUPERQUANT (0.632). These discrepancies were greatest with genotype 2 (bDNA/SUPERQUANT= 0.772; bDNA/MONITOR=0. 456; SUPERQUANT/MONITOR= 0.299). This correlation was influenced by viraemia level and was better at lower viral loads. The proportion of sera with undetectable viral load was 15% with bDNA, 9.7% with MONITOR and 7.7% with SUPERQUANT. For the three measurements, the best cut-offs of sustained response to IFN treatment were located at their detection threshold. Among patients with viral load below the detection level, a sustained response was observed in 35% tested with bDNA, 38% with MONITOR and 80% with SUPERQUANT. Hence a stronger correlation was observed between bDNA and SUPERQUANT than between either of these assays and MONITOR. SUPERQUANT was the most sensitive assay and this greater sensitivity was associated with a better predictive value of treatment response.
authors.affiliation: Department of Hepatology, Hôtel-Dieu, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Pradat
authors.forename: P
authors.initials: P
authors.lastname: Chossegros
authors.forename: F
authors.initials: F
authors.lastname: Bailly
authors.forename: P
authors.initials: P
authors.lastname: Pontisso
authors.forename: G
authors.initials: G
authors.lastname: Saracco
authors.forename: S
authors.initials: S
authors.lastname: Sauleda
authors.forename: M
authors.initials: M
authors.lastname: Thursz
authors.forename: H
authors.initials: H
authors.lastname: Tillmann
authors.forename: H
authors.initials: H
authors.lastname: Vlassopoulou
authors.forename: A
authors.initials: A
authors.lastname: Alberti
authors.forename: J H
authors.initials: JH
authors.lastname: Braconier
authors.forename: J I
authors.initials: JI
authors.lastname: Esteban
authors.forename: S
authors.initials: S
authors.lastname: Hadziyannis
authors.forename: M
authors.initials: M
authors.lastname: Manns
authors.forename: M
authors.initials: M
authors.lastname: Rizzetto
authors.forename: H C
authors.initials: HC
authors.lastname: Thomas
authors.forename: C
authors.initials: C
authors.lastname: Trépo
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D012367:RNA, Viral / Q000032:analysis; D011933:Reagent Kits, Diagnostic; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic; D007372:Interferons